Human papillomavirus: Current status and issues of vaccination

Archives of Virology

Volumn 159, Issue 2, 2014, Pages 199-205

  Malik, Heena ^a   Khan, Fahim H ^a   Ahsan, Haseeb ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

SUBUNIT VACCINE; WART VIRUS VACCINE;

CLASSIFICATION; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; REVIEW; UTERINE CERVIX TUMOR; UTILIZATION REVIEW; VACCINATION;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, SUBUNIT;

EID: 84895076239     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-013-1827-z     Document Type: Review

References (60)

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17-27.
2. Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31: 14-19.
3. Campo M (2003) Papillomavirus and disease in humans and animals. Vet Comp Oncol 1: 3-14.
4. zur Hausen H (2009) Papillomaviruses in the causation of human cancers-a brief historical account. Virology 384: 260-265.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
6. Ramet J, van Esso D, Meszner Z, European Academy of Paediatrics Scientific Working Group on Vaccination (2011) Position paper-HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians. Eur J Pediat 170: 309-321.
7. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L (2007) Human papillomavirus and HPV vaccines: a review. Bull World Health Org 85: 719-726.
8. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markwitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 297: 813-819.
9. National Cancer Registry Project (NCRP) Biennial Report (2001) New Delhi: Indian Council of Medical Research.
10. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401(1): 70-79.
11. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, Harwood CA, de Koning MN, Naldi L, Nindl I, Pawlita M, Pfister H, Proby CM, Quint WG, ter Schegget J, Waterboer T, Weissenborn S, Feltkamp MC, EPI-HPV-UV-CA group (2010) Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 70(23): 9777-9786.
12. zur Hausen H (1987) Papillomaviruses in human cancer. Appl Pathol 5(1): 19-24.
13. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5): 342-350.
14. Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110(5): 525-541.
15. Schelhaas M, Ewers H, Rajamäki ML, Day PM, Schiller JT, Helenius A (2008) Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog 4(9): e1000148.
16. Okun MM, Day PM, Greenstone HL, Booy FP, Lowy DR, Schiller JT, Roden RB (2001) L1 interaction domains of papillomavirus L2 necessary for viral genome encapsidation. J Virol 75: 4332-4342.
17. Holmgren SC, Patterson NA, Ozbun MA, Lambert PF (2005) The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol 79: 3938-3948.
18. Finnen RL, Erickson KD, Chen XS, Garcea RL (2003) Interactions between papillomavirus L1 and L2 capsid proteins. J Virol 77: 4818-4826.
19. Ishii Y, Ozaki S, Tanaka K, Kanda T (2005) Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding. Virus Genes 2005(31): 321-328.
20. Kämper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M (2006) A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80: 759-768.
21. Campos S, Ozbun MA (2009) Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes. PLoS One 4: e4463.
22. Florin L, Becker KA, Lambert C, Nowak T, Sapp C, Strand D, Streeck RE, Sapp M (2006) Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2. J Virol 80: 6691-6696.
23. Garcea RL, Chen X (2007) Papillomavirus structure and assembly. In: Garcea RL, DiMaio D (eds) The papillomaviruses. Springer, New York, pp 69-88.
24. Danos O, Engel LW, Chen EY, Yaniv M, Howley PM (1983) Comparative analysis of the human type 1a and bovine type 1 papillomavirus genomes. J Virol 46: 557-566.
25. Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP (2010) Mechanisms of cell entry by human papillomaviruses: an overview. Virol J 2010(7): 11.
26. Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-560.
27. Grabowska AK, Riemer AB (2012) The Invisible Enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J 6: 249-256.
28. Ashrafi GH, Brown DR, Fife KH, Campo MS (2006) Downregulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res 120: 208-211.
29. Ashrafi GH, Haghshenas M, Marchetti B, Campo MS (2006) E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 119: 2105-2112.
30. Antonsson A, Payne E, Hengst K, McMillan NA (2006) The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res 26: 455-461.
31. Wang KL (2007) Human papillomavirus and vaccination in cervical cancer. Taiwan J Obstet Gynecol 46: 352-362.
32. Urman CO, Gottlieb AB (2008) New viral vaccines for dermatologic disease. J Am Acad Dermatol 58: 361-370.
33. Rowen D (2005) Human papillomavirus infection and anogenital warts. In: Kumar B, Gupta S (eds) Sexually Transmitted Infections, 1st edn. Elsevier, New Delhi, pp 215-224.
34. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574): 1693-1702.
35. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G (2007) HPV PATRICIA study group. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580): 2160-2170 Erratum in: Lancet. 2007; 370(9596): 1414.
36. Mello MM, Abiola S, Colgrove J (2012) Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination. Am J Public Health 102: 893-898.
37. Garcini LM, Galvan T, Barnack-Tavlaris JL (2012) The study of human papillomavirus (HPV) vaccine uptake from a parental perspective: A systematic review of observational studies in the United States. Vaccine 30: 4588-4595.
38. Liu TY, Hussein WM, Toth I, Skwarczynski M (2012) Advances in peptide-based human papillomavirus therapeutic vaccines. Curr Top Med Chem 12(14): 1581-1592.
39. Pandhi D, Sonthalia S (2011) Human papilloma virus vaccines: Current scenario. Indian J Sex Transm Dis 32(2): 75-85.
40. Bonati M, Garattini S (2009) Controlling cervical cancer. Pharmacoeconomics 27(2): 91-93.
41. Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 356: 1928-1943.
42. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W (2010) HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 25: 8352-8358.
43. Castellsague X, Munoz N (2003) Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 31: 20-28.
44. Kaarthigeyan K (2012) Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol 33: 7-12.
45. Schiffman M, Castle PE, Jeronim J, Rodrigue AC, Wacholde S (2007) Human papillomavirus and cervical cancer. Lancet 370: 890-907.
46. Kohaar I, Thakur N, Salhan S, Batra S, Singh V, Sharma A et al (2007) TNFα -308 G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cellular Oncol 29: 249-256.
47. Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila A, Snijders PJ et al (2003) Human papillomavirus and risk factors for cervical cancer in Chennai, in India: a case control study. Int J Cancer 107: 127-213.
48. Sowjanya AP, Jain M, Poli UR (2005) Prevalence and distribution of high-risk human papillomavirus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 5: 116-122.
49. Indian Council of Medical Research (2010) Annual Report, 2010-2011. http://www. icmr. nic. in/annual/2010-11/non_comm. pdf.
50. Franceschi S (2005) The International Agency for Research on Cancer (IARC) commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Result Cancer Res 166: 277-297.
51. Jones SB (1999) Cancer in the developing world: a call to action. Brit Med J 319: 505-508.
52. Schiller JT, Nardelli-Haefliger D (2006) Chapter 17: Second generation HPV vaccines to prevent cervical cancer. Vaccine 24(Suppl 3): S3/147-S3/153.
53. Stanley M (2010) Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 23: 70-75.
54. Clinical Trials (2013) Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001 AM3). http://clinicaltrials. gov/ct2/show/NCT00543543.
55. Kiatpongsan S, Campos NG, Kim JJ (2012) Potential Benefits of Second-Generation Human Papillomavirus Vaccines. PLOS ONE 7(11): e48426.
56. Khan FH (2009) The Elements of Immunology, 1st edn. Pearson Education, India.
57. Leder C, Kleinschmidt JA, Wiethe C, Muller M (2001) Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 75: 9201-9209.
58. Huang CH, Monie A, Alvarez RD, Wu TC (2007) DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 39: 679-689.
59. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT (1998) Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95: 1800-1805.
60. Roden RB, Ling M, Wu TC (2004) Vaccination to Prevent and Treat Cervical Cancer. Human Path 35(8): 971-982.